Drug intelligence / Profile preview

WSD0329

Development stage: Preclinical
Lead developer: Wayshine Biopharm
Modality: Small Molecules

Overview

WSD0329 is a blood-brain barrier (BBB) penetrating small molecule inhibitor developed by Wayshine Biopharm, Inc. for the treatment of glioblastoma (GBM), brain cancer, and central nervous system (CNS) metastasis. It functions by inhibiting cancer cell migration through the targeting of the MerTK/p-SRC/p-STAT3/Kras signaling pathway in GBM-like stem cells. By modulating these key signaling nodes, WSD0329 aims to address the invasive nature of glioblastoma and prevent the progression of metastatic brain tumors.

Targets

SRC (Proto-oncogene tyrosine-protein kinase Src)STAT3 (Signal Transducer and Activator of Transcription 3)MERTK (MER proto-oncogene, tyrosine kinase)

Beyond the preview

Go deeper on WSD0329.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSD0329.